<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721705</url>
  </required_header>
  <id_info>
    <org_study_id>RenewTM NCP-5-1001</org_study_id>
    <nct_id>NCT03721705</nct_id>
  </id_info>
  <brief_title>Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type</brief_title>
  <official_title>A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renew Research, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Navitas Clinical Research, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinEdge, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Renew Research, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment&#xD;
      due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single&#xD;
      blind, parallel design, multi-site study intends to examine the efficacy and safety of&#xD;
      RenewTM NCP-5 therapy in the treatment of Cognitive Impairment due to Alzheimer's Disease or&#xD;
      Mild Dementia of the Alzheimer's Type. Subjects will be prospectively randomized to treatment&#xD;
      or sham (in a 1:1 ratio) using stratification for Cognitive Impairment due to Alzheimer's&#xD;
      Disease or Mild Dementia of the Alzheimer's Type, and Cardiovascular Risk (CVR) score at&#xD;
      multiple sites. Subjects, ages 55-85, will be consented for 13 months and will receive&#xD;
      thirty-five 60-minute RenewTM NCP-5 treatment sessions during a 7-to-12-week initial&#xD;
      treatment period, and then transition to a lower frequency maintenance period (twice a week)&#xD;
      for a total treatment period of 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 23, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to either the treatment group or the sham group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The vADAS-cog assessment includes 17 subscale scores. The total score is the sum of all scaled scored from 0-120. The higher values represent more cognitive impairment. The change in vADAS-cog scores from baseline at the timepoints of 12, 18, and 24 weeks is averaged together for each patient. The primary outcome measure is the average of those values for all patients in a group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Related Adverse Events as Assessed by MedDRA.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Related Serious Adverse Events as Assessed by MedDRA.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Mild Dementia</condition>
  <condition>Cognitive Decline</condition>
  <condition>Dementia, Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renew NCP-5</intervention_name>
    <description>Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
    <arm_group_label>Sham Arm</arm_group_label>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be 55-85 years of age at the time of signing the informed consent&#xD;
&#xD;
          2. Be able to provide consent or have legally authorized representative/caregiver who can&#xD;
             provide consent&#xD;
&#xD;
          3. Be able to read and write in English or Spanish&#xD;
&#xD;
          4. Have a clinical diagnosis consistent with 2011 National Institute of Aging -&#xD;
             Alzheimer's Association (NIA-AA) &quot;core clinical criteria&quot; guidelines for: (i) The&#xD;
             diagnosis of dementia due to Alzheimer's disease or (ii) The diagnosis of mild&#xD;
             cognitive impairment due to Alzheimer's disease:&#xD;
&#xD;
               -  Montreal Cognitive Assessment (MOCA) score of greater than or equal to 11&#xD;
&#xD;
               -  All required checkboxes within the study checklist for &quot;The diagnosis of probable&#xD;
                  AD dementia&quot; must be &quot;yes&quot; or&#xD;
&#xD;
               -  All required checkboxes within the study checklist for &quot;The diagnosis of mild&#xD;
                  cognitive impairment due to Alzheimer's disease&quot; must be &quot;yes&quot;&#xD;
&#xD;
          5. Stable medications for past 30 days and plan to remain on stable medications for the&#xD;
             first 24 weeks of study participation for treatment of chronic conditions.&#xD;
&#xD;
          6. Subject should have a caregiver, study partner or companion (which can be a domestic&#xD;
             party) and may conduct the assessment over the phone if they don't accompany the&#xD;
             participant).&#xD;
&#xD;
          7. Must have the potential to improve by at least 2 points or more in the Vascular&#xD;
             Dementia Assessment Scale cognitive subscale (vADAS-COG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling or unable to participate in study procedures&#xD;
&#xD;
          2. Weight &gt;297 lbs. or &gt;135 kg at screening&#xD;
&#xD;
          3. Major confounding neurodegenerative or psychiatric disorder unrelated to the condition&#xD;
             under study, including:&#xD;
&#xD;
               1. History of clinically-evident stroke&#xD;
&#xD;
               2. Current uncontrolled epileptic seizures or epilepsy&#xD;
&#xD;
               3. Multiple Sclerosis or Parkinson's Disease&#xD;
&#xD;
               4. Current clinically significant major psychiatric disorder (e.g., Major Depressive&#xD;
                  Disorder) according to the Fifth Edition of Diagnostic and Statistical Manual of&#xD;
                  Mental Disorders (DSM-V) criteria or significant psychiatric symptoms (e.g.,&#xD;
                  hallucinations) that could impair the completion of the study&#xD;
&#xD;
          4. Anyone with active or history of cerebral hemorrhage including subdural &amp; subarachnoid&#xD;
             or cerebral aneurysm&#xD;
&#xD;
          5. Evidence of any of the following (based on Section 4.1.1(D) of the 2011 NIA-AA&#xD;
             guidelines on The diagnosis of dementia due to Alzheimer's disease):&#xD;
&#xD;
               1. Substantial concomitant cerebrovascular disease, defined by a history of a stroke&#xD;
                  temporally related to the onset or worsening of cognitive impairment; or the&#xD;
                  presence of multiple or extensive infarcts or severe white matter hyperintensity&#xD;
                  burden&#xD;
&#xD;
               2. Core features of Dementia with Lewy bodies other than dementia itself&#xD;
&#xD;
               3. Prominent features of behavioral variant frontotemporal dementia&#xD;
&#xD;
               4. Prominent features of semantic variant primary progressive aphasia or&#xD;
                  nonfluent/agrammatic variant primary progressive aphasia&#xD;
&#xD;
               5. Evidence for another concurrent, active neurological disease, non-neurological&#xD;
                  medical comorbidity or use of medication that could have a substantial effect on&#xD;
                  cognition&#xD;
&#xD;
          6. In the opinion of the investigator, any current clinically-significant systemic&#xD;
             illness or medical condition that is likely to result in deterioration of the&#xD;
             subject's condition, affect the subject's safety during the study, or to be&#xD;
             incompatible with performance of the study procedures, including:&#xD;
&#xD;
               1. History of head trauma with a diagnosis of moderate to severe traumatic brain&#xD;
                  injury&#xD;
&#xD;
               2. Known current substantially elevated intracranial pressure&#xD;
&#xD;
               3. Known current significant sleep deprivation&#xD;
&#xD;
               4. Known history (within five years) or current significant drug abuse or alcoholism&#xD;
&#xD;
          7. Any contraindication for MRI such as insulin pumps or pacemakers, including dual&#xD;
             chamber pacemakers where atrial pacing may interfere with RenewTM NCP-5 inflation&#xD;
             timing sequence&#xD;
&#xD;
          8. Hypotension as defined as &lt;80/50 blood pressure at the time of screening&#xD;
&#xD;
          9. Ongoing uncontrolled severe hypertension (≥ 180 mmHg systolic or ≥ 110 mmHg diastolic&#xD;
&#xD;
         10. Heart rates &lt; 35 or &gt;125 beats per minute (BPM) at screening&#xD;
&#xD;
         11. Current uncontrolled arrhythmia. Controlled arrhythmia should have beat-to-beat,&#xD;
             cycle-length variability less than ±25% at rest.&#xD;
&#xD;
         12. Current congestive heart failure&#xD;
&#xD;
         13. Cardiac catheterization within two weeks, any surgical intervention within six weeks&#xD;
             before RenewTM NCP-5 treatment or a hip or knee replacement within 3 months as long as&#xD;
             rehab is complete and symptoms have resolved.&#xD;
&#xD;
         14. Known presence of abdominal aortic aneurysm&#xD;
&#xD;
         15. Existing aortic insufficiency grade II or higher (regurgitation can prevent diastolic&#xD;
             augmentation)&#xD;
&#xD;
         16. Current or past venous thrombosis or thromboembolism&#xD;
&#xD;
         17. Current limiting peripheral vascular disease with history strongly suggestive of lower&#xD;
             extremity ischemia or claudication, arterial occlusive disease (aortoiliac,&#xD;
             ileofemoral, or femoral popliteal)&#xD;
&#xD;
         18. Demonstrable deficiency in sensation in lower extremities as a result of diabetes or&#xD;
             other medical condition&#xD;
&#xD;
         19. Current bleeding disorders.&#xD;
&#xD;
         20. Current use of major anti-coagulation therapy (such as Heparin therapy or Coumadin®&#xD;
             therapy) with International Normalized Ratio (INR) &gt; 1.5&#xD;
&#xD;
         21. Current severe pulmonary disease that prevents the subject from lying supine&#xD;
&#xD;
         22. Presence of local infection, vasculitis, burn, open wound, or bone fracture on any&#xD;
             limb which would prevent the ability to perform the RenewTM NCP-5 treatment&#xD;
&#xD;
         23. Current use of medications that in the investigator's judgement are incompatible with&#xD;
             the study goals&#xD;
&#xD;
         24. Significant changes in existing medical plans for treatment of cognitive impairment or&#xD;
             dementia in last three months and/or or planned changes during the trial&#xD;
&#xD;
         25. Presence of any of the contraindications for using the RenewTM NCP-5 device&#xD;
&#xD;
         26. Athletic injuries, including Charley horses, pulled muscles and/or edematous muscles;&#xD;
             necrotizing cellulitis in the past 30 days which would prevent the ability to perform&#xD;
             the RenewTM NCP-5 treatment (evaluate and treat prior to RenewTM NCP-5 treatment)&#xD;
&#xD;
         27. Unwilling or unable to maintain stable exercise regimen throughout the trial&#xD;
&#xD;
         28. Participation in any clinical drug trial 30 days or five half-lives, whichever is&#xD;
             longer, prior to screening visit&#xD;
&#xD;
         29. Use of any device to increase cerebral blood flow in the past 30 days.&#xD;
&#xD;
         30. History of claustrophobia.&#xD;
&#xD;
         31. Subject unable to lay supine for 90 minutes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy Tally</last_name>
    <role>Study Director</role>
    <affiliation>Stage 2 Innovations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charter Research</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Dade Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Advantages, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <results_first_submitted>March 23, 2022</results_first_submitted>
  <results_first_submitted_qc>March 23, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2022</results_first_posted>
  <last_update_submitted>April 19, 2022</last_update_submitted>
  <last_update_submitted_qc>April 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03721705/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03721705/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03721705/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sham Arm</title>
          <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Suitable Study Partner</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early Termination Due to Coronavirus Disease 2019 (COVID-19)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sham Arm</title>
          <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="7.69"/>
                    <measurement group_id="B2" value="68.1" spread="7.20"/>
                    <measurement group_id="B3" value="68.3" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mild Cognitive Impairment (MCI) due to AD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mild AD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low/Medium Cardiovascular Risk</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High/Very High Cardiovascular Risk</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks.</title>
        <description>The vADAS-cog assessment includes 17 subscale scores. The total score is the sum of all scaled scored from 0-120. The higher values represent more cognitive impairment. The change in vADAS-cog scores from baseline at the timepoints of 12, 18, and 24 weeks is averaged together for each patient. The primary outcome measure is the average of those values for all patients in a group.</description>
        <time_frame>24 weeks</time_frame>
        <population>There were 7 treatment and 11 active sham with missing VADAS-cog values at 12, 18, and 24 weeks. These 18 subjects with all 3 primary time points missing discontinued the study. These values were multiply imputed from the longitudinal model as pre-specified.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham Arm</title>
            <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks.</title>
          <description>The vADAS-cog assessment includes 17 subscale scores. The total score is the sum of all scaled scored from 0-120. The higher values represent more cognitive impairment. The change in vADAS-cog scores from baseline at the timepoints of 12, 18, and 24 weeks is averaged together for each patient. The primary outcome measure is the average of those values for all patients in a group.</description>
          <population>There were 7 treatment and 11 active sham with missing VADAS-cog values at 12, 18, and 24 weeks. These 18 subjects with all 3 primary time points missing discontinued the study. These values were multiply imputed from the longitudinal model as pre-specified.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.76" spread="1.54"/>
                    <measurement group_id="O2" value="-5.31" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Related Adverse Events as Assessed by MedDRA.</title>
        <time_frame>24 weeks</time_frame>
        <population>3 participants from active sham group were migrated to treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham Arm</title>
            <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Related Adverse Events as Assessed by MedDRA.</title>
          <population>3 participants from active sham group were migrated to treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Related Serious Adverse Events as Assessed by MedDRA.</title>
        <time_frame>24 weeks</time_frame>
        <population>3 participants from active sham group were migrated to treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham Arm</title>
            <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Related Serious Adverse Events as Assessed by MedDRA.</title>
          <population>3 participants from active sham group were migrated to treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The period from signing informed consent to the end of the study treatment follow-up (Month 12).</time_frame>
      <desc>3 participants from active sham group were migrated to treatment group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sham Arm</title>
          <description>The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.&#xD;
Renew NCP-5: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Coronavirus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic Lateral Sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Rate and Rhythm Disorders, Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Upset</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dental pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>General pain and discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infections, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Coronavirus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation/Injury</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Limb Fractures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscles/Tendon/Ligament injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Site specific injuries, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Spinal Fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration/Fluid Volume Decrease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Numbness/Tingling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Itch</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Skin discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Billy Tally, CEO</name_or_title>
      <organization>Renew Research</organization>
      <phone>949-545-8466</phone>
      <email>bill2@stage2innovations.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

